A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs LIK 066 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 01 Oct 2018 Status changed from active, no longer recruiting to completed.
- 26 Sep 2018 This trial has been completed in Austria.
- 31 Aug 2018 Biomarkers information updated